top of page

STOCK SELECTIONS

August 19, 2024

Overview

AIZ (Assurant) is an international insurance provider focusing on housing and lifestyle markets. Lifestyle accounts for 80% of revenues from mobile device protection, extended service products for consumer electronics as well as auto insurance. Housing provides conventional homeowner insurance products. Revenues and earnings have grown consistently for the past number of years and this is likely to continue. AIZ has solid finances, is reducing debt and plans more share repurchases.

​

Earnings and Yield

 AIZ exceeded expectations in the last four quarters and guidance is strong going forward.  Dividend is 1.5%.

​

Valuation

PE is 10 compared with an average of 15 and forward PE is 11. The industry average is 8. PE to growth is 2.2. PS is 0.8 compared with an average of 0.9 and industry value of 1.6.

​​

Technical

Simple MA:        

5 day                     186.06

10 day                   179.69

20 day                   176.11

50 day                   171.09                

100day                  173.33

200day                  173.48

 

PSAR                     Buy since August 9, 2024

ADX (14)               25.6 and rising

DI +                       33.1 and rising

DI –                        13.5 and falling

 

MACD (12,26)       3.40

SMA (9)                  2.77          

OBV                       Below the 20 day MA and falling

​​​​​

Prices

Close                      188.75 on August 19, 2024                   

52 wk hi                  189.77

Ave target              212.00

 

Summary

AIZ is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

​​​​

August 12, 2024

Overview

EG (Everest Re Group) underwrites property/casualty (P/C)reinsurance and insurance in the United States and abroad. Reinsurance, which is essentially insurance for insurance companies accounts for 70% of revenues. Major events such as hurricanes and other natural disasters affect claims and therefore profitability of insurers. EG has demonstrated solid financial performance in meeting these challenges and has reported record underwriting profit and strong increases in operating, investment and net income. This is attributed through rate increases leading to market expansion and underwriting discipline.

​

Earnings and Yield

EG exceeded expectations in three of the last four quarters. The 0.7% miss in the last quarter has not affected guidance going forward. Dividend is 2.0%.

​

Valuation

PE is 5 compared with an average of 9.5 and forward PE is 6. The industry average is 8.3. PE to growth is 2.2. PS is 0.8 compared with an average of 0.9 and industry value of 1.3.

​

Technical

Simple MA:        

5 day                     361.78

10 day                   368.00

20 day                   377.69

50 day                   378.11                

100day                  378.60

200day                  378.61

 

PSAR                     Sell since July 24, 2024

ADX (14)               19.2 and rising

DI +                       19.0 and flat

DI –                        30.0 and falling

 

MACD (12,26)       negative 7.71

SMA (9)                  negative 1.59          

OBV                       Below the 20 day MA and both are falling

​​​​

Prices

Close                      360.91 on August 12, 2024                   

52 wk hi                  417.92

Ave target              423.00

 

Summary

EG is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

​​​​

August 16, 2024

Overview

MRK (Merck) is a global pharmaceutical company with a blockbuster cancer drug Keytruda that should continue to expand its indications and therefore revenues for the next several years. MRK also derives stable revenues from animal health and vaccines and has a promising pipeline for drugs treating pulmonary hypertension, RSV, and cancer drugs that could be combined with Keytruda. MRK price dropped sharply on July 30 along with the rest of the market and even though there was a 6% positive earnings surprise that day. The stock now appears undervalued in view of its good prospects.

​

Earnings and Yield

MRK exceeded expectations in the last four quarters and provided strong guidance going forward. Dividend is 2.7%.

​

Valuation

PE is 17 compared with an average of 13 and forward PE is 14. The industry average is 21. PE to growth is 1.7. PS is 4.9 compared with an average of 4.2 and industry value of 7.6.

​​​

Technical

Simple MA:           

5 day                     113.69  

10 day                   113.29

20 day                   117.6

50 day                   123.98

100day                  126.33

200day                  120.62

 

PSAR                     SELL since July 30, 2024

ADX (14)                31.6 and rising

DI +                       15.2 and flat

DI –                        29.9 and falling

 

MACD (12,26)       negative 5.83

SMA (9)                 negative 5.42

               

OBV                      Below the 20 day MA and both are falling

​​​​

Prices

Close                     113.67 on August 16, 2024         

52 wk hi                 134.63

Ave target             140.00

​​​​​

Summary

MRK is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

July 1, 2024

Overview

PFE (Pfizer) is one of the major, multinational pharmaceutical company with a wide range of current and late pipeline products in a variety of high growth areas including oncology, immunology and vaccines. It has divested its consumer and generic product lines to focus on its research programs to drive growth. PFE stock has lagged behind its peers over the past year, primarily because of the loss of revenue from its COVID vaccines and treatments. This is likely an overreaction to its prospects which appear strong over the next few years.

​

Earnings and Yield

PFE exceeded expectations in the last four quarters and maintained strong guidance going forward. EPS estimates have been stable over the past month. Dividend is very attractive at 5.9%.

​

Valuation

PE is 20 compared with an average of 12 and forward PE is 12. Industry PE is 20.  P/S for the company is 2.6 compared to an average of 3.4 The industry value is 7.5.

​

Technical

Simple MA:        

5 day                     27.98

10 day                   27.76

20 day                   28.12

50 day                   27.85                  

100day                  27.50

200day                  28.79

 

PSAR                     SELL since July 1, 2024

ADX (14)               14.0 and falling

DI +                       28.1 and rising

DI –                        24.4 and falling

 

MACD (12,26)        negative 0.45

SMA (9)                  negative 0.45           

OBV                        Above the 20 day MA and rising

​

Prices

Close                      28.22 on July 1, 2024                   

52 wk hi                  37.80

Ave target              33

 

Summary

PFE is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

​​

July 21, 2024

Overview

GL (Globe Life) is an insurance holding company that primarily sells life and health insurance to lower and middle income households across the country. Its strengths include higher premium income, improved underwriting margins as a result of dealing in a relatively non-competitive market. GL has strong net investment income and good finance leading to high excess cash flow generation.

​

Earnings and Yield

GL exceeded expectations in three of the last four quarters and maintained strong guidance going forward. EPS estimates have been rising over the past month. Dividend is 1.1%.

​

Valuation

PE is 8 compared with an average of 10 and forward PE is 8. Industry PE is 13. P/S for the company is 1.3 compared to an average of 1.9 The industry value is 1.8.

​

Technical

Simple MA:           

5 day                     88.14   

10 day                   85.79

20 day                   84.29

50 day                   83.66

100day                  91.96

200day                  105.84

 

PSAR                     BUY since July 11, 2024

ADX (14)                18.3 and rising

DI +                       31.1 and rising

DI –                        15.3 and falling

 

MACD (12,26)       negative 1.80

SMA (9)                 negative 1.11

               

OBV                      Above the 20 day MA and rising

​​

Prices

Close                     88.26 on July 19, 2024         

52 wk hi                 132.00

Ave target             105.00

​​

Summary

GL is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

July 22, 2024

Overview

PYPL (Paypal) is one of the largest online payment providers that offers secure transactions to both customers and merchants. Its strong peer-to-peer payment service has led to growth in total payment volume and it is also growing in mobile volumes and expanding into banking initiatives. PYPL continues to create strategic partnerships with companies such as Visa, MasterCard, Google, Facebook and banks including JP Morgan and Bank of America.

​

Earnings and Yield

PYPL exceeded expectations in three of the last four quarters and maintained strong guidance going forward. EPS estimates have been rising over the past month. There is no dividend.

​

Valuation

PE is 15 compared with an average of 25 and forward PE is 14. P/S for the company is 1.0 compared to an average of 5.5 The industry value is 2.6.

​

Technical

Simple MA:        

5 day                     60.63

10 day                   60.18

20 day                   59.53

50 day                   61.67                  

100day                  62.77

200day                  60.70

 

PSAR                     BUY since July 5, 2024

ADX (14)               14.3 and falling

DI +                       25.5 and rising

DI –                        24.3 and rising

 

MACD (12,26)       0.35

SMA (9)                  negative 0.98           

OBV                        Above the 20 day MA and both are rising

​​

Prices

Close                      60.77 on July 22, 2024                   

52 wk hi                  76.54

Ave target              74.00

 

Summary

PYPL is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

​​​

July 26, 2024

Overview

TSM (Taiwan Semiconductor Manufacturing) is the world’s largest semiconductor company. Its innovative strategy is based on the foundry model in which it makes semiconductors for the specific needs of a company rather than for general sale. Its quality makes it a supplier to major companies such as Apple, Tesla and Nvidia. TSM earns stable revenue from smartphones and growth from the GPU’s that power the data centres that are required to train AI applications. TSM stock price dropped along with other companies during the recent pullback in technology and its price is now more attractive than it has been in some time.

​

Earnings and Yield

TSM exceeded expectations in the last four quarters and maintained strong guidance going forward. EPS estimates have been rising over the past month. Dividend is 1%.

​

Valuation

PE is 29 compared with an average of 18 and forward PE is 25. PE to growth is 0.95

​

Technical

Simple MA:           

5 day                     164.24   

10 day                   170.13

20 day                   176.18

50 day                   168.42

100day                  154.20

200day                  129.83

 

PSAR                     SELL since July 17, 2024

ADX (14)                31.5 and flat

DI +                       15.0 and falling

DI –                        32.9 and rising

 

MACD (12,26)       negative 2.51

SMA (9)                 2.65

               

OBV                      Below the 20 day MA and falling

​​

Prices

Close                     161.94 on July 26, 2024         

52 wk hi                 193.47

Ave target             205.00

​​​

Summary

TSM is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

July 30, 2024

Overview

RCL (Royal Caribbean Cruises) is a leading international cruise line. RCL operates focuses on the middle segment of the cruise industry although is expanding to appeal to luxury and younger customers. It has performed strongly since recovery from the pandemic. RCL has benefited from strong cruising demand and loyal customers. Its strategy of filling its ships without discounting prices has led to increased profits per customer. RCL plans to growth through new ships, products and experiences including private destinations.

​

Earnings and Yield

RCL exceeded expectations in the last four quarters and maintained strong guidance going forward. EPS estimates have been rising over the past month. There is no dividend.

​

Valuation

PE is 15 compared with an average of 12 and forward PE is 13. PE to growth is 0.4. PS is 2.3 compared with and average of 2.0 and industry value of 1.4

​

Technical

Simple MA:        

5 day                     156.43

10 day                   161.84

20 day                   162.16

50 day                   156.30                

100day                  145.75

200day                  128.92

 

PSAR                     Sell since July 25, 2024

ADX (14)               22.3 and falling

DI +                       20.0 and rising

DI –                        24.3 and rising

 

MACD (12,26)       1.80

SMA (9)                  4.26           

OBV                        Above the 20 day MA and both are rising

​​​

Prices

Close                      156.94 on July 30, 2024                   

52 wk hi                  173.37

Ave target              175.00

 

Summary

RCL is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

​​​

July 31, 2024

Overview

STZ (Constellation Brands) produces and markets beer, wine and spirits. It is the third largest beer company but holds the top position in the coveted premium and imported beer segment, led by Mexican brands Modelo and Corona. STZ is trying to grow in the high-end wine category with brands such as Robert Mondavi and also has small operations in spirits and cannabis. Growth has been strongest in the beer business where it is increasing volumes, revenues and profits compared to a decline in the beer industry as a whole. Growth is expected to continue through marketing and capital investments, funded by consistently strong cash flows.

​

Earnings and Yield

STZ exceeded expectations in the last four quarters and maintained strong guidance going forward. EPS estimates have been rising over the past month. Dividend in 1.5%.

​

Valuation

PE is 19 compared with an average of 25 and forward PE is 19. PE to growth is 1.7. PS is 4.1 compared with an average of 4.5 and industry value of 9.9.

​​

Technical

Simple MA:           

5 day                     247.50   

10 day                   246.73

20 day                   250.04

50 day                   252.30

100day                  257.17

200day                  249.86

 

PSAR                     SELL since July 31, 2024

ADX (14)                17.6 and flat

DI +                       18.9 and flat

DI –                        26.3 and flat

 

MACD (12,26)       negative 5.03

SMA (9)                 negative 4.67

               

OBV                      Above the 20 day MA and flat while 20d MA is rising

​​​

Prices

Close                     245.16 on July 31, 2024         

52 wk hi                 274.87

Ave target             302.00

​​​​

Summary

STZ is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

May 31, 2024

Overview

CNC (Centene) offers health care services to around 28 million members. It is the largest Medicaid managed care organization in the United States and its individual exchange program, which catches people pushed off Medicaid rolls, is growing rapidly. Its Commercial segment is also expanding. Combining both organic and inorganic (acquisitions) growth, revenues have increased for the past 20 years including a CAGR of 30% from 2015-2022. The company expects growth to continue in upcoming years.

​

Earnings and Yield

CNC exceeded expectations in the last four quarters and maintained strong guidance going forward. EPS revisions have been up over the past month. There is no dividend.

​

Valuation

PE is 11 compared with an average of 13.5 and forward PE is 11. Industry PE is 16. PE/growth is 0.9.  P/S for the company is 0.3 compared to an average of 0.3 The industry value is 0.8.

​

Technical

Simple MA:        

5 day                     71.68

10 day                   74.82

20 day                   75.73

50 day                   74.90                  

100day                  76.05

200day                  73.22

 

PSAR                     SELL since May 24, 2024

ADX (14)                21.1 and rising

DI +                       18.0 and falling

DI –                        44.4 and falling

 

MACD (12,26)        0.25

SMA (9)                  1.24           

OBV                        Below the 20 day MA and both are falling

​

Prices

Close                      71.59 on May 31, 2024                   

52 wk hi                  81.42

Ave target              89

 

Summary

CNC is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

​

June 17, 2024

Overview

ADSK (Autodesk) develops model-based software for customers in Architecture, Engineering, Construction, Manufacturing and Entertainment. Its products help create design, manufacturing and operations solutions. Revenue comes from sales, maintenance and service agreements for its products. Ongoing growth should come from increased demand for its cloud platform as well as a growing suite of software products. The stock price rose more than 6 % on June 17.

​

Earnings and Yield

ADSK exceeded expectations in the last four quarters and maintained strong guidance going forward. EPS estimates have been stable over the past month. There is no dividend.

​

Valuation

PE is 44 compared with an average of 50 and forward PE is 41. Industry PE is 16. PE/growth is 3.0.  P/S for the company is 7.6 compared to an average of 9.1 The industry value is 9.0.

​

Technical

Simple MA:           

5 day                     224.80   

10 day                   220.24

20 day                   216.27

50 day                   219.24

100day                  238.03

200day                  228.54

 

PSAR                     BUY since June 3, 2024

ADX (14)                18.9 and stable

DI +                       34.6 and rising

DI –                        24.0 and falling

 

MACD (12,26)       negative 1.47

SMA (9)                 negative 2.55

               

OBV                      Above the 20 day MA and both are rising

​

Prices

Close                     240.51 on June 17, 2024         

52 wk hi                 279.53

Ave target             267.00

​

Summary

ADSK is an attractive stock to purchase with the goal of gaining  ≥ 5% within the next 6 months.

Subscribe to get notified of our stock selections.

Thanks for submitting!

Stock Wealth Safely does not provide investment advice. This site simply lists the stocks we have chosen for our investment portfolio and shows how they have performed over time. Past performance is not a predictor of future results. Individual investment results may vary. All investing involves risk of loss.

bottom of page